May 24, 2021 8:30am EDT Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
May 19, 2021 8:30am EDT Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients
May 12, 2021 6:30am EDT Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues
May 05, 2021 8:30am EDT Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
Apr 28, 2021 8:30am EDT Veru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th
Apr 21, 2021 8:30am EDT Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
Mar 02, 2021 8:30am EST Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference
Mar 01, 2021 8:30am EST Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
